Optimi Health Launches Ibogaine Initiative Following U.S. Executive Order on Psychedelic Drug Development
核心洞察
Optimi Health launched its Ibogaine Initiative to manufacture and supply ibogaine using its Health Canada-licensed GMP platform, targeting opioid use disorder, PTSD, and traumatic brain injury treatments.
President Trump signed an Executive Order directing federal agencies to accelerate psychedelic drug research and patient access, with FDA Commissioner confirming IND clearance for ibogaine clinical trials.
The Executive Order includes a $50 million federal allocation through ARPA-H (搜索) to match state investments, potentially pairing with Texas's $50 million ibogaine research commitment.
Optimi Health Corp (搜索). has launched its Ibogaine Initiative to extend its Health Canada-licensed GMP manufacturing platform to include ibogaine production, positioning the company to serve emerging demand following a landmark U.S. Executive Order that establishes federal pathways for psychedelic drug development.
The initiative comes as President Donald Trump signed an Executive Order on April 18, 2026, directing federal agencies to accelerate research, regulatory review, and patient access pathways for psychedelic drug products, including ibogaine. FDA Commissioner Marty Makary confirmed Investigational New Drug (IND) clearance for ibogaine at the signing, enabling sponsors to advance U.S. clinical trials.
Federal Funding and Research Framework
The Executive Order directs the Advanced Research Projects Agency for Health (ARPA-H (搜索)) to match qualifying state-level investments in psychedelic research, beginning with a $50 million federal allocation. This funding may be paired with Texas's previously authorized $50 million ibogaine research commitment, potentially creating a $100 million research initiative.
The Order also extends federal Right to Try eligibility to psychedelic drug products and contemplates priority review mechanisms, such as the Commissioner's National Priority Voucher, to potentially shorten FDA review timelines.
Ibogaine's Therapeutic Potential
Ibogaine is a naturally occurring alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central and West Africa. It has been studied for its potential to interrupt opioid withdrawal and craving, and for its effects on substance-use disorders, post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI).
A 2024 Stanford-led study of U.S. Special Operations veterans, published in Nature Medicine, reported reductions in PTSD, depression, anxiety, and functional disability in a cohort following a single ibogaine treatment protocol.
Commercial Operations and Market Position
Optimi is already commercial-stage in Australia, where authorized physicians are actively prescribing the company's MDMA for PTSD and its naturally derived psilocybin for treatment-resistant depression (TRD). In parallel, the company supplies pharmaceutical-grade MDMA and psilocybin to clinical trials and special access programs globally.
As part of its U.S. market readiness strategy, Optimi obtained an FDA Establishment Identifier (FEI) number in 2025, supporting its ability to engage with U.S. regulatory and commercial pathways as they evolve.
"Optimi already manufactures and supplies GMP-grade psychedelic drug products to patients under regulated frameworks, and today in Australia, doctors are prescribing our MDMA for PTSD and psilocybin for treatment-resistant depression," said Dane Stevens, Chief Executive Officer and Co-Founder of Optimi Health.
Manufacturing Infrastructure
The company operates as a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia. Products are currently available for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
Stevens noted that the regulatory developments "move ibogaine from what has historically been a fragmented, primarily offshore ecosystem toward a defined U.S. regulatory and funding pathway. The ibogaine market took shape in a meaningful way over the weekend following a U.S. Executive Order, and it will require high-quality, regulated supply."
The company is positioning its fully GMP, Health Canada-licensed manufacturing infrastructure to support the next phase of market development as federal policy frameworks evolve to accommodate psychedelic therapeutics.